Press Release<< Back
Verastem to Host Analyst and Investor Day on May 2, 2018
The agenda will include an in-depth discussion of the Company’s lead oral oncology candidate, duvelisib, including the unmet need of patients, where phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitors fit into the treatment paradigm and the opportunity for duvelisib in the growing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) population and beyond.
The program will also feature key opinion leaders in the hematologic oncology field, including:
Jennifer Brown, MD, PhD
Associate Professor of Medicine,
Harvard Medical SchoolDirector, and Director, CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute
Ian Flinn, MD, PhD
Director, Blood Cancer Research Program at
Sarah Cannon Research Institute, and Lead Investigator of the DUO and DYNAMO Studies
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center and NYC Health+ Hospitals/Bellevue
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
Physician, Medical Director of the
Chronic Lymphocytic Leukemia (CLL) Societyand CLL Patient
Lori Kunkel, MD
Oncology Drug Development Expert and Biotech Advisor, Member of the Board of Directors at
Tocagen Inc., Former Chief Medical Officer, Pharmacyclics
Kindly reach out to
A live and archived webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at www.verastem.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
For more information, please visit www.verastem.com.
Marianne M. Lambertson, 781-292-4273
Vice President, Corporate Communications
Investor Relations/Public Relations